Hugh A Barton
Overview
Explore the profile of Hugh A Barton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
805
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoer D, Barton H, Paini A, Bartels M, Ingle B, Domoradzki J, et al.
Toxicol Appl Pharmacol
. 2022 Feb;
440:115922.
PMID: 35176293
Although external concentrations are more readily quantified and often used as the metric for regulating and mitigating exposures to environmental chemicals, the toxicological response to an environmental chemical is more...
2.
Tan Y, Barton H, Boobis A, Brunner R, Clewell H, Cope R, et al.
Regul Toxicol Pharmacol
. 2021 Oct;
127:105070.
PMID: 34718074
Top dose selection for repeated dose animal studies has generally focused on identification of apical endpoints, use of the limit dose, or determination of a maximum tolerated dose (MTD). The...
3.
Generaux G, Lakhani V, Yang Y, Nadanaciva S, Qiu L, Riccardi K, et al.
Pharmacol Res Perspect
. 2019 Oct;
7(6):e00523.
PMID: 31624633
Many compounds that appear promising in preclinical species, fail in human clinical trials due to safety concerns. The FDA has strongly encouraged the application of modeling in drug development to...
4.
Aleo M, Shah F, Allen S, Barton H, Costales C, Lazzaro S, et al.
Chem Res Toxicol
. 2019 Sep;
33(1):223-238.
PMID: 31532188
The hepatic risk matrix (HRM) was developed and used to differentiate lead clinical and back-up drug candidates against competitor/marketed drugs within the same pharmaceutical class for their potential to cause...
5.
Jones H, Zhang Z, Jasper P, Luo H, Avery L, King L, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Aug;
8(10):738-747.
PMID: 31464379
Monoclonal antibody (mAb) pharmacokinetics (PK) have largely been predicted via allometric scaling with little consideration for cross-species differences in neonatal Fc receptor (FcRn) affinity or clearance/distribution mechanisms. To address this,...
6.
Li R, Barton H
Clin Pharmacokinet
. 2017 Jun;
57(4):491-503.
PMID: 28653144
Background: Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is unclear. A previous study hypothesizes that, without applying an...
7.
Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy
Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton H, Grimwood S, et al.
Pharm Res
. 2016 Mar;
33(5):1305-6.
PMID: 26964545
No abstract available.
8.
Li R, Maurer T, Sweeney K, Barton H
AAPS J
. 2016 Mar;
18(3):746-56.
PMID: 26951483
The physiologically based pharmacokinetic (PBPK) model for liver transporter substrates has been established previously and used for predicting drug-drug interactions (DDI) and for clinical practice guidance. So far, nearly all...
9.
Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton H, Grimwood S, et al.
Pharm Res
. 2016 Jan;
33(4):1003-17.
PMID: 26718955
Objectives: To assess the ability of a previously developed hybrid physiology-based pharmacokinetic-pharmacodynamic (PBPKPD) model in rats to predict the dopamine D2 receptor occupancy (D2RO) in human striatum following administration of...
10.
Shah F, Leung L, Barton H, Will Y, Rodrigues A, Greene N, et al.
Toxicol Sci
. 2015 Jul;
147(2):500-14.
PMID: 26206150
Severe drug-induced liver injury (DILI) remains a major safety issue due to its frequency of occurrence, idiosyncratic nature, poor prognosis, and diverse underlying mechanisms. Numerous experimental approaches have been published...